Antimalarial activity

Antimalarial activity refers to the pharmacological capacity of a substance to inhibit the growth, development, or survival of Plasmodium parasites, the causative agents of malaria [WHO, 2023]. This term does not describe a single molecular target (such as a specific receptor or enzyme) but rather a broader phenotypic outcome resulting from the disruption of various essential biological processes within the parasite [Nature Reviews Drug Discovery, 2021]. These processes include hemoglobin degradation in the parasite food vacuole, nucleic acid synthesis, and mitochondrial energy production, which are critical across different stages of the parasite life cycle [NIH, 2022]. Because 'antimalarial activity' is a biological effect rather than a discrete target, it is used as a primary endpoint in drug discovery assays to evaluate the potency of new chemical entities. Understanding this activity is vital for addressing the global health challenge posed by artemisinin resistance and for developing next-generation therapies targeting both the asexual erythrocytic stage and the sexual gametocyte stage of infection [PubMed, 2022].

Other names

Antimalarial effectPlasmodicidal activityAnti-plasmodial activityMalaria parasite inhibition

Antimalarial activity is achieved through diverse molecular mechanisms depending on the drug class, including the inhibition of heme detoxification (e.g., quinolines), disruption of folate biosynthesis (e.g., antifolates), interference with mitochondrial electron transport (e.g., atovaquone), and induction of oxidative stress via protein alkylation (e.g., artemisinins) [NIH StatPearls, 2023; WHO, 2023].